Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/13952
|
| Title: | Artificial-intelligence-assisted discovery of genetic factors for precision medicine of antiplatelet therapy in diabetic peripheral artery disease |
| Authors: | Yeh, CH;Chou, YJ;Tsai, TH;Hsu, PWC;Li, CH;Chan, YH;Tsai, SF;Ng, SC;Chou, KM;Lin, YC;Juan, YH;Fu, TC;Lai, CC;Sytwu, HK;Tsai, TF |
| Contributors: | Institute of Molecular and Genomic Medicine;National Institute of Infectious Diseases and Vaccinology |
| Abstract: | An increased risk of cardiovascular events was identified in patients with peripheral artery disease (PAD). Clopidogrel is one of the most widely used antiplatelet medications. However, there are heterogeneous outcomes when clopidogrel is used to prevent cardiovascular events in PAD patients. Here, we use an artificial intelligence (AI)-assisted methodology to identify genetic factors potentially involved in the clopidogrel-resistant mechanism, which is currently unclear. Several discoveries can be pinpointed. Firstly, a high proportion (>50%) of clopidogrel resistance was found among diabetic PAD patients in Taiwan. Interestingly, our result suggests that platelet function test-guided antiplatelet therapy appears to reduce the post-interventional occurrence of major adverse cerebrovascular and cardiac events in diabetic PAD patients. Secondly, AI-assisted genome-wide association study of a single-nucleotide polymorphism (SNP) database identified a SNP signature composed of 20 SNPs, which are mapped into 9 protein-coding genes (SLC37A2, IQSEC1, WASHC3, PSD3, BTBD7, GLIS3, PRDM11, LRBA1, and CNR1). Finally, analysis of the protein connectivity map revealed that LRBA, GLIS3, BTBD7, IQSEC1, and PSD3 appear to form a protein interaction network. Intriguingly, the genetic factors seem to pinpoint a pathway related to endocytosis and recycling of P2Y12 receptor, which is the drug target of clopidogrel. Our findings reveal that a combination of AI-assisted discovery of SNP signatures and clinical parameters has the potential to develop an ethnic-specific precision medicine for antiplatelet therapy in diabetic PAD patients. |
| Date: | 2022-01 |
| Relation: | Biomedicines. 2022 Jan;10:Article number 116. |
| Link to: | http://dx.doi.org/10.3390/biomedicines10010116 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2227-9059&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000747739900001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85123617833 |
| Appears in Collections: | [徐唯哲] 期刊論文
[蔡世峯] 期刊論文
[司徒惠康] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI000747739900001.pdf | | 3945Kb | Adobe PDF | 206 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
